We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Kwee
Yong
kwee.yong@ucl.ac.uk
Rethina
Shritharan
r.shritharan@ucl.ac.uk
Dr
Kwee
Yong
kwee.yong@ucl.ac.uk
Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissueNeoplasms of uncertain or unknown behaviour
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Myeloma(MM) is a common bone marrow cancer with over 5,000 patients diagnosed annually in the UK. Patients with MM have cancerous cells in their bone marrow that grow in an uncontrolled fashion and although new treatments have been developed for MM in the last 5 years, it remains an incurable disease, with nearly 3000 deaths yearly. MM is always preceded by defined precursor conditions, known as monoclonal gammopathy of uncertain significance (MGUS) and smouldering myeloma (SMM). However, only 7% of MGUS patients and 50% of SMM patients develop MM over a 5-year period. In the UK, patients are only given anti-MM treatment when the cancer causes damage within the body as the benefit of giving treatment in the pre-cancerous state is uncertain.
There is increased understanding that the development of MM occurs due to changes in the cancer’s genetic make-up (genome) and in the cells surrounding the tumour in the bone marrow (immune microenvironment). The cells in the immune microenvironment can support tumour growth and lead to resistance to drugs used to kill MM cells.
This project correlates changes in the genetic make-up of the precancerous cells to progression to MM compared to that in the bloodstream and changes that also occur within the cells in the immune microenvironment at the time of disease progression. By identifying which changes in the tumour genome cause the precancerous condition to develop into MM, we can develop a way to risk stratify patients with sMM and treat them according to their risk status. Furthermore, by defining which immune cells are important in helping to drive the conversion of sMM to MM, we can potentially develop new treatments to target not only the tumour cells but also the immune cells helping to drive disease progression.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Clinical Laboratory Study;
You can take part if:
You may not be able to take part if:
Patients under the age of 18. - Patients with active symptomatic myeloma at diagnosis. - Patients with no evidence of MGUS, sMM or MM. - Patients with a known diagnosis of MGUS or sMM for more than 5 years. - Patients with rapidly rising paraprotein or serum free light chains suggestive of progressive disease at time of diagnosis or inclusion into study.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Rethina
Shritharan
r.shritharan@ucl.ac.uk
Dr
Kwee
Yong
kwee.yong@ucl.ac.uk
Dr
Kwee
Yong
kwee.yong@ucl.ac.uk
The study is sponsored by University College London and funded by CANCER RESEARCH UK .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 46567
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
